Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Second-generation cisplatin analogs].

Y Ariyoshi, K Ota

    Gan to Kagaku Ryoho. Cancer & Chemotherapy
    |April 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Cisplatin analogues like carboplatin offer reduced renal toxicity for cancer treatment. While less nephrotoxic, these agents can cause myelosuppression, particularly impacting platelet counts.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Experimental and clinical studies on dysregulation of magnesium metabolism and the aetiopathogenesis of multiple sclerosis.

    Magnesium research·1992
    Same author

    Mechanism of proteinuria in nephrotic syndrome.

    Acta medica Okayama·1992
    Same author

    Effects of nicergoline on calcium and magnesium deposition in the central nervous system tissues of rats maintained on low-calcium diets.

    The Journal of international medical research·1992
    Same author

    Alpha 2-adrenergic receptors are involved in the suppression of luteinizing hormone release during acute fasting in the ovariectomized estradiol-primed rats.

    Neuroendocrinology·1992
    Same author

    [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].

    Gan to kagaku ryoho. Cancer & chemotherapy·1992
    Same author

    [Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].

    Gan to kagaku ryoho. Cancer & chemotherapy·1992
    Same journal

    [A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [Recent Advances in the Treatment of HER2-Altered Solid Tumors].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    Same journal

    [BRAF-Mutant Solid Tumor].

    Gan to kagaku ryoho. Cancer & chemotherapy·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Cisplatin (CDDP) has been a cornerstone in cancer therapy since 1972, effective against various tumors.
    • CDDP's use is limited by dose-limiting toxicities, primarily renal impairment, emesis, neuropathy, hearing loss, and anemia.
    • Development of second-generation cisplatin analogues aims to reduce toxicity while maintaining efficacy.

    Purpose of the Study:

    • To review the clinical trial results of emerging cisplatin analogues.
    • To compare the toxicity and efficacy profiles of these new agents against cisplatin.
    • To highlight the potential of novel platinum-based chemotherapy drugs.

    Main Methods:

    • Review of published clinical trial data for cisplatin analogues.
    • Analysis of preclinical studies evaluating efficacy and toxicity.

    Related Experiment Videos

  • Summary of Phase I and Phase II trial findings for carboplatin, iproplatin, and other Japanese analogues.

    • Main Results:

    • Carboplatin (CBDCA) demonstrates reduced nephrotoxicity compared to CDDP, with myelosuppression (thrombocytopenia) as the dose-limiting factor.
    • Carboplatin shows activity in advanced ovarian, head and neck, lung, and urogenital cancers.
    • Iproplatin (CHIP) and other Japanese analogues also exhibit promising activity in preclinical and early clinical studies.

    Conclusions:

    • Second-generation cisplatin analogues, notably carboplatin, offer a potentially safer alternative to cisplatin due to decreased renal toxicity.
    • Myelosuppression is a key toxicity to monitor with carboplatin and related compounds.
    • Ongoing trials are evaluating the therapeutic potential of novel platinum-based chemotherapy agents in various cancers.